Granules USA Inc Pharmaceutical Import Profile — United States (DGFT 2022–2026)

Name: Granules USA Inc Pharmaceutical Import Records from India — 9 Products, $71.0M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Granules USA Inc — Pharmaceutical Importer Profile (2026) | 9 Products, $71.0M Trade | TransData Nexus

Granules USA Inc

Pharmaceutical Importer · United States · Analgesics & Antipyretics Focus · $71.0M Total Trade · DGFT Verified

Granules USA Inc is a pharmaceutical importer based in United States with a total trade value of $71.0M across 9 products in 4 therapeutic categories. Based on 1,453 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Granules USA Inc sources from 2 verified Indian suppliers, with Granules India Limited accounting for 99.2% of imports.

Granules USA Inc — Import Portfolio & Supplier Network

Granules USA Inc import network — 9 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Granules USA Inc?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Granules India Limited	$40.1M	1,002	99.2%
Vkt Pharma Private Limited	$324.0K	9	0.8%

Granules USA Inc sources from 2 verified Indian suppliers across .

What Formulations Does Granules USA Inc Import?

Formulation	Value	Ships
Tylenol 8hr-arthritis pain-acetaminophener tablets-650MG 225s	$1.8M	40
Compresso pap 90	$1.7M	36
Acetaminophen extended release tablets	$1.1M	21
Fexofenadine hydrochloride tablets USP	$1.0M	20
Compresso pap 90	$850.0K	17
Compresso pap 80	$641.2K	13
Ibuprofen tablets USP 200MG	$550.0K	11
Fexofenadine hydrochloride tablets USP 180MG	$536.3K	13
Loratadine tablets USP 10MG	$507.2K	15
Tylenol 8hr-muscle aches pain-acetaminophen er tablets-650MG 100s	$456.4K	11
Acetaminophen extended release tablets USP 650MG	$451.0K	10
Acetaminophen rapid release gelcaps	$450.0K	9
Compresso pap 90 cpf(acetaminophen directly compressible granules)	$419.0K	9
Cetirizine hcl tablets USP 10MG	$391.7K	12
Ibuprofen tablets USP 200MG(caplet	$350.0K	7

Granules USA Inc imports 471 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 9 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Acetaminophen	Analgesics & Antipyretics	$28.6M	572	6.8%	2
2	Amino	Nutritional Supplements	$28.6M	572	4.9%	2
3	Fexofenadine	Antihistamines & Allergy	$5.3M	107	3.2%	3
4	Ibuprofen	Analgesics & Antipyretics	$2.6M	52	0.4%	12
5	Loratadine	Antihistamines & Allergy	$2.0M	48	0.6%	11
6	Cetirizine	Antihistamines & Allergy	$1.6M	31	0.9%	18
7	Guaifenesin	Respiratory & OTC	$1.5M	40	3.4%	4
8	Aspirin	Analgesics & Antipyretics	$415.4K	24	1.1%	16
9	Diphenhydramine	Antihistamines & Allergy	$350.0K	7	1.1%	9

Granules USA Inc imports 9 pharmaceutical products across 4 categories into United States totaling $71.0M.

Granules USA Inc — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Granules USA Inc. is a prominent pharmaceutical importer and distributor based in Parsippany, New Jersey. Established in 2010, the company serves as the U.S. distribution arm of Granules India Limited, a global pharmaceutical manufacturer. Granules USA Inc. specializes in importing, distributing, and marketing generic pharmaceutical products, leveraging its parent company's manufacturing capabilities to supply essential medicines to the U.S. healthcare market.

The company operates as a critical link between Granules India's manufacturing operations and the U.S. pharmaceutical supply chain, ensuring timely delivery and regulatory compliance. Granules USA Inc. supports healthcare providers and pharmacies across the United States, contributing to the availability of affordable generic medications.

2Distribution Network

Granules USA Inc. maintains a robust distribution network to efficiently serve the U.S. market. The company operates multiple distribution centers, including facilities in Parsippany, New Jersey, and Mount Arlington, New Jersey. These strategically located centers enable the company to manage logistics effectively and ensure timely delivery of pharmaceutical products across the United States.

3Industry Role

Granules USA Inc. plays a pivotal role in the U.S. pharmaceutical supply chain as a primary wholesaler and distributor of generic medications. By importing finished pharmaceutical formulations from India, the company ensures a steady supply of affordable generic drugs to the U.S. market, thereby enhancing access to essential healthcare products. Its operations bridge the gap between Indian manufacturers and U.S. healthcare providers, facilitating the availability of cost-effective pharmaceutical solutions.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Granules USA Inc

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Granules USA Inc. exhibits a high degree of sourcing concentration, with 99.2% of its imports from India supplied by Granules India Limited. This single-source dependency indicates a strategic choice to leverage the manufacturing strengths and established relationship with its parent company. The substantial volume of shipments—1,453 in total—suggests a stable and reliable partnership, reducing the risk of supply chain disruptions. However, this concentration also means that any operational challenges faced by Granules India Limited could directly impact Granules USA Inc.'s supply chain.

2Supply Chain Resilience

Granules USA Inc.'s supply chain resilience is closely tied to its relationship with Granules India Limited, its primary supplier. The company's import data indicates a consistent flow of shipments, reflecting a stable supply chain. However, the limited number of suppliers—only two verified Indian suppliers—suggests a lack of diversification. This concentration could pose risks if Granules India Limited faces production or logistical challenges. Additionally, the reliance on a single supplier may limit Granules USA Inc.'s ability to negotiate better terms or diversify its product offerings.

3Strategic Implications

Importing Pharmaceuticals into United States — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United States

1Regulatory Authority & Framework

In the United States, the Food and Drug Administration (FDA) serves as the primary regulatory authority overseeing the importation and distribution of pharmaceutical products. The FDA enforces regulations to ensure the safety, efficacy, and quality of drugs entering the U.S. market. Key legislation governing pharmaceutical imports includes the Federal Food, Drug, and Cosmetic Act, which outlines the standards for drug approval and importation. The Drug Enforcement Administration (DEA) also plays a role in regulating controlled substances, ensuring that imported drugs comply with federal laws.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products entering the U.S. are stringent. Manufacturers and importers must register with the FDA and obtain an establishment registration number. Additionally, imported drugs must comply with Good Manufacturing Practice (GMP) standards. The FDA recognizes GMP certifications from various international bodies, including the European Union (EU) GMP, World Health Organization (WHO) GMP, and Pharmaceutical Inspection Co-operation Scheme (PIC/S). These certifications ensure that manufacturing processes meet international quality standards.

Quality & Labeling

Granules USA Inc — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Granules USA Inc. focuses on importing generic pharmaceutical products across various therapeutic categories, including analgesics, nutritional supplements, and antihistamines. The company's product strategy is driven by market demand for affordable and effective medications. By sourcing these products from India, Granules USA Inc. leverages cost-effective manufacturing to provide high-quality generics to the U.S. market. This approach aligns with the growing emphasis on cost containment in healthcare and the increasing acceptance of generic drugs among consumers and healthcare providers.

2Sourcing Profile

Granules USA Inc. employs a sourcing strategy that heavily relies on its parent company, Granules India Limited, for the supply of generic pharmaceutical formulations. This strategy ensures consistency in product quality and supply chain reliability. The company's preference for finished pharmaceutical formulations over raw Active Pharmaceutical Ingredients (APIs) indicates a focus on ready-to-market products that meet U.S. regulatory standards. India's established pharmaceutical manufacturing capabilities and cost advantages make it a strategic partner for Granules USA Inc.'s procurement needs.

3Market Positioning

Seller's Guide — How to Become a Supplier to Granules USA Inc

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to collaborate with Granules USA Inc. by offering high-quality generic pharmaceutical products that meet U.S. regulatory standards. Gaps in Granules USA Inc.'s current sourcing include potential diversification of suppliers to mitigate risks associated with single-source dependency. Indian exporters can seize this opportunity by ensuring compliance with FDA regulations, obtaining necessary certifications, and demonstrating the ability to meet the quality and supply chain requirements of the U.S. market.

2Requirements & Qualifications

Indian exporters seeking to supply Granules USA Inc. and the U.S. market must obtain FDA approval for their manufacturing facilities and products. This includes compliance with GMP standards recognized by the FDA. Exporters must also ensure that their products meet FDA labeling requirements and are subject to batch testing and stability studies. Additionally, obtaining certifications such as EU GMP, WHO GMP, or PIC/S can enhance credibility and facilitate market entry.

3How to Approach

Frequently Asked Questions — Granules USA Inc

What products does Granules USA Inc import from India?

Granules USA Inc imports 9 pharmaceutical products across 4 categories. Top imports: Acetaminophen ($28.6M), Amino ($28.6M), Fexofenadine ($5.3M), Ibuprofen ($2.6M), Loratadine ($2.0M).

Who supplies pharmaceuticals to Granules USA Inc from India?

Granules USA Inc sources from 2 verified Indian suppliers. The primary supplier is Granules India Limited (99.2% of imports, $40.1M).

What is Granules USA Inc's total pharmaceutical import value?

Granules USA Inc's total pharmaceutical import value from India is $71.0M, based on 1,453 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Granules USA Inc focus on?

Granules USA Inc imports across 4 categories. The largest: Analgesics & Antipyretics (44.5%), Nutritional Supplements (40.3%), Antihistamines & Allergy (13.0%).

Get Full Granules USA Inc Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.